{
    "nctId": "NCT03208465",
    "officialTitle": "Empagliflozin Versus Sitagliptin Therapy for Improvement of Myocardial Perfusion Reserve in Diabetic Patients With Coronary Artery disease_ELITE Trial",
    "inclusionCriteria": "* Men or women at least 19 years of age\n* Type 2 diabetes mellitus\n* Stable coronary artery disease\n* Global myocardial perfusion reserve (MPR) index \\< 2.5\n* The patient or guardian agrees to the study protocol and the schedule of clinical and dynamic SPECT follow-up, and provides informed, written consent, as approved by the appropriate Institutional Review Board/Ethical Committee of the respective clinical site.\n* Must have minimum age of 19 Years",
    "exclusionCriteria": "* Contraindications to empagliflozin, Sitagliptin\n* DPP4 inhibitors or Sodium-glucose cotransporter-2(SGLT2) inhibitors within the previous 4 weeks\n* Insulin requiring diabetes\n* Poor glucose control (HbA1C\\>10 %)\n* Acute coronary syndrome\n* Stent placement within the previous 6 months\n* Previous coronary artery bypass graft surgery within the previous 6 months\n* Planned revascularization within 6 months\n* Heart failure requiring loop diuretics\n* Severe left ventricular hypertrophy (left ventricular septal wall thickness \\> 13mm)\n* Significant renal disease manifested by creatinine clearance of \\< 30 ml/min)\n* Hepatic disease or biliary tract obstruction, or significant hepatic enzyme elevation (alanine transaminase or Aspartate Aminotransferase \\> 3 times upper limit of normal)\n* Radiopaque material implanted in the chest wall (metal, silicone, etc.)\n* Contraindication to adenosine stress test\n* Any clinically significant abnormality identified at the screening visit, physical examination, laboratory tests, or electrocardiogram which, in the judgment of the Investigator, would preclude safe completion of the study.\n* Patient's pregnant or breast-feeding or child-bearing potential\n* Expected life expectancy \\< 1 year\n* Unwillingness or inability to comply with the procedures described in this protocol"
}